| [1]Guida G,Iolascon G,Gimigliano F,et al.Development of knowledge about osteoporosis in the world of orthopedics and traumatology[J].Aging Clin Exp Res,2011,23(2 Suppl):8-9.[2]Hofbauer LC,Rachner TD.More DATA to guide sequential osteoporosis therapy[J].Lancet,2015,386(9999):1116-1118.[3]Issack PS,Lauerman MH,Helfet DL,et al.Alendronate inhibits PTH (1-34)-induced bone morphogenetic protein expression in MC3T3-E1 preosteoblastic cells[J].HSS J,2007,3(2):169-172.[4]Qin L,Raggatt LJ,Partridge NC.Parathyroid hormone: a double-edged sword for bone metabolism[J].Trends Endocrinol Metab,2004,15(2):60-65.[5]Hodsman AB,Bauer DC,Dempster DW,et al.Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use[J].Endocr Rev,2005,26(5):688-703.[6]Amugongo SK,Yao W,Jia J,et al.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats[J].Bone,2014,67:257-268.[7]Wang H,Wang R,Wang Z,et al.ClC-3 chloride channel functions as a mechanically sensitive channel in osteoblasts[J].Biochem Cell Biol,2015,93(6):558-565.[8]Li J,Zhao Z,Liu J,et al.MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF-beta1/Smads pathway[J].Cell Prolif,2010,43(4):333-343.[9]Krause DS,Fulzele K,Catic A,et al.Differential regulation of myeloid leukemias by the bone marrow microenvironment[J].Nat Med,2013,19(11):1513-1517.[10]Ohyama Y,Tanaka T,Shimizu T，et al.Runx2/Smad3 complex negatively regulates TGF-β-induced connective t1 growth factor gene expression in vascular smooth muscle cells[J].J Atheroscler Thromb,2012,19(1):23-35.[11]Wang H,Mao Y,Zhang B,et al.Chloride channel ClC-3 promotion of osteogenic differentiation through Runx2[J].J Cell Biochem,2010,111(1):49-58.[12]Zhu H,Fang J,Luo X,et al.A survey of bone mineral density of healthy Han adults in China[J].Osteoporos Int,2010,21(5):765-772.[13]Ishtiaq S,Fogelman I,Hampson G.Treatment of post-menopausal osteoporosis: beyond bisphosphonates[J].J Endocrinol Invest,2015,38(1):13-29.[14]Gourlay ML,Fine JP,Preisser JS,et al.Bone-density testing interval and transition to osteoporosis in older women[J].N Engl J Med,2012,366(3):225-233.[15]Song J,Jin Z,Chang F,et al.Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs[J].Med Sci Monit,2014,20:2624-2632.[16]Qiu T,Wu X,Zhang F,et al.TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling[J].Nat Cell Biol,2010,12(3):224-234.[17]Atfi A,Baron R.PTH battles TGF-β in bone[J].Nat Cell Biol,2010,12(3):205-207.[18]Gramley F,Lorenzen J,Koellensperger E,et al.Atrial fibrosis and atrial fibrillation: The role of the TGF-β1 signaling pathway[J].Int J Cardiol,2010,143(3):405-413.[19]Okamoto F,Kajiya H,Toh K,et al.Intracellular ClC-3 chloride channels promote bone resorption in vitro through organelle acidification in mouse osteoclasts[J].Am J Physiol Cell Physiol,2008,294(3):C693-C701.[20]Wang H,Huo N,Li F,et al.Osteogenic role of endosomal chloride channels in MC3T3-E1 cells[J].Mol Cell Biochem,2010,342(1/2):191-199.[21]卢晓琳，王欢，杨磊，等.甲状旁腺激素对成骨细胞中ClC-3氯通道表达及成骨分化影响的研究[J].现代生物医学进展,2015,15(10):1830-1835. |
